Rapid Identification of Pathogenic Bacteria in Blood causing Sepsis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2SB1AI094781-04
Agency Tracking Number: SB1AI094781
Amount: $1,995,172.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PAR16-027
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
500 S AUSTRALIAN AVE, West Palm Beach, FL, 33401-6223
DUNS: 827877486
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RAY MARTINO
 (650) 938-6200
 rmartino@isensesystems.com
Business Contact
 PAUL RHODES
Phone: (650) 938-6200
Email: prhodes@evolvedmachines.com
Research Institution
N/A
Abstract
Sepsis is the leading cause of deaths in US hospitals contributing to or causing of all US hospital deaths and is the most expensive condition treated in US hospitals costing more than $ billion annually More than million blood culture bottles are produced annually with a market size greater than $ B in the US and EU alone The two year phase II period spanned February to February R AI The developments funded in part by this grant have created a new paradigm to diagnose blood stream infection causing sepsis The work of this grant has assisted in creating the SpecID blood culture system which the company is now commercializing The SpecID solution replaces the present step process for characterization of blood samples currently divided into detection of infection an obligatory Gram stain for all positive cultures performed on the bench by trained technician and then species ID by MALDI TOF again requiring skilled sample preparation The SpecID solution combines faster detection more accurate Gram status determination than the benchtop stain and ID more accurate than MALDI in a single fully automated step which reduces the time to ID streamlines lab workflow and saves significant cost The result is improved patient outcomes and improved lab operating performance The objectives of this Commercialization Readiness Pilot CRP Program proposal reflect the key goals not supported by the Phase II or Phase IIB programs but required to achieve commercial market entry of the SpecID blood culture system including development of blood culture media manufacturing processes development of quality control and documentation systems FDA strategy to achieve k approval and development of the SpecID blood culture instrument and blood culture bottle sensor attachment Sepsis is the leading cause of deaths in US hospitals contributing to or causing of all US hospital deaths and is the most expensive condition treated in US hospitals costing for than $ billion annually Rapid identification of the infection is critical for effective treatment The ultimate goal of this project is to bring hospitals a new technology solution that reduces the time to identification in a single automated instrument The result is improved patient outcomes and importantly in today s cost critical healthcare system the solution is less expensive than current practice

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government